Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

Leukemia. 2021 Mar;35(3):887-892. doi: 10.1038/s41375-020-0989-4. Epub 2020 Jul 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bortezomib / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / pathology
  • Mutation*
  • Proteasome Endopeptidase Complex / chemistry*
  • Proteasome Endopeptidase Complex / genetics
  • Proteasome Inhibitors / therapeutic use*
  • Tumor Cells, Cultured

Substances

  • Proteasome Inhibitors
  • Bortezomib
  • PSMB5 protein, human
  • Proteasome Endopeptidase Complex